HomeWebinarsUnlocking Potential Formulation Strategies for Poorly Soluble Molecules

Unlocking Potential Formulation Strategies for Poorly Soluble Molecules


Poor drug solubility is one of the most inhibiting factors in drug product development. The Developability Classification System (DCS) was developed to assist scientists in optimizing formulations of poorly soluble molecules. Thereby it guides various formulation strategies to overcome solubility issues:

  1. Dissolution enhancement via wetting agents like Poloxamer 188 which accelerate the dissolution profile.
  2. Solid-state modification via solid dispersion technology to enhance fundamentally the solubility. In this context, hot-melt extrusion and spray drying are some of the key technologies to cover a wide range of model APIs: from traditional small to emerging molecules, including the exciting new drug class of PROTACs.

In this webinar, you will learn:

  • Why it is important to distinguish between dissolution and solubility-limited molecules to identify the right formulation strategy
  • How Poloxamers can be used to accelerate dissolution of poorly soluble molecules
  • How solid dispersion technology enhances the solubility and stability of traditional and emerging small molecules (e.g. PROTACs) due to its excellent matrix-forming ability


Markus Lubda, Ph.D.

Markus Lubda, Ph.D.


Strategic Marketing Manager

Markus joined Merck seven years ago and is a strategic marketing manager, responsible for the development and positioning of an excipient portfolio for oral solid dosage form applications. His focus is on identifying engineered particles to enhance solubility and bioavailability.

He holds a Ph.D. in biology/chemistry from the Technical University of Darmstadt and is a biomolecular engineer.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?